Tag: Spectranetics

Merging the portfolios and strengths of Philips and Spectranetics

At the recent Vascular Interventional Advances 2017 conference (VIVA; 11–14 September, Las Vegas, USA), Vascular News caught up with Philips' Atul Gupta (Global Chief...

Spectranetics announces FDA approval of Stellarex drug-coated balloon

Spectranetics has announced receipt of US Food and Drug Administration (FDA) pre-market approval of the Stellarex drug-coated balloon (DCB), designed to restore and maintain blood flow...

Philips to acquire Spectranetics

Royal Philips and The Spectranetics Corporation have entered into a definitive merger agreement. Pursuant to the agreement, Philips will commence a tender offer to acquire all of...

Global cohorts report drug-coated balloon success above the knee and “promising”...

Three global registries reported fresh data at the 2017 Leipzig Interventional Course (LINC; 24–27 January, Leipzig, Germany), all of which showed encouraging outcomes for...

Combined 12-month analysis of ILLUMENATE EU and US trials presented at...

At LINC 2017 (24–27 January, Leipzig, Germany), Sean Lyden (Cleveland Clinic, Cleveland, USA) presented an update on the 12-month results of the European and...

Positive results for Spectranetics Stellarex demonstrated in ILLUMENATE 12-month data

The final 12-month results of the Stellarex (Spectranetics) drug-coated balloon ILLUMENATE Global Study have found high primary patency and freedom from clinically driven target...

Scott Hutton appointed general manager of Vascular Intervention at Spectranetics

Scott Hutton has been named general manager of Vascular Intervention at Spectranetics. In this role, Hutton will report directly to the president and chief executive...

Spectranetics receives CE mark for Stellarex 0.014 drug-coated balloon

Spectranetics’ Stellarex 0.014” drug-coated angioplasty balloon has received the CE mark. The Stellarex 0.014” device is designed to treat small vessels, below-the-knee disease, and challenging...

Stellarex ILLUMENATE 12-month pivotal results are “top-tier” in complex patients

Spectranetics has announced that the final 12-month results of the Stellarex drug-coated balloon ILLUMENATE pivotal trial have been presented at the Transcatheter Cardiovascular Therapeutics...

Spectranetics files FDA pre-market approval application for the Stellarex drug-coated balloon

Spectranetics has submitted its pre-market approval application for the Stellarex drug-coated angioplasty balloon to the US Food and Drug Administration (FDA). Stellarex is designed to restore...

First randomised Stellarex DCB data show 12-month outcomes superior to percutaneous...

Marianne Brodmann of Medical University Graz, Austria, has presented the final 12-month results of the Stellarex (Spectranetics) ILLUMENATE drug-coated balloon European randomised clinical trial...